Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-03

GLUE vs PRME: stock comparison and AI forecast

Monte Rosa Therapeutics, Inc. (GLUE) and Prime Medicine, Inc. (PRME) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Biological Products, (No Diagnostic Substances)

GLUE Monte Rosa Therapeutics, Inc.

Market Cap
$907M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Biological Products, (No Diagnostic Substances)

PRME Prime Medicine, Inc.

Market Cap
$805M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

GLUE · PRME

Key facts

  • GLUE is 1.1 times larger than PRME by market capitalization ($907M against $805M).
  • GLUE turns -657.2% of its revenue into net income, against -4678.6% for PRME.
  • PRME carries 5.26 times debt per unit of equity, against 0.42 times for GLUE.
  • Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricGLUEPRME
Market Cap$907M$805M
P/B Ratio1.86x20.23x
EPS$-1.76$-1.18
Book Value/Share$5.71$0.22
Revenue/Share$0.29–
FCF/Share$-0.38$-0.86

Profitability & Margins

MetricGLUEPRME
ROE-33.1%-472.0%
ROA-23.3%-75.5%
ROIC-28.8%-90.4%
Operating Margin-741.8%-4893.4%
Net Margin-657.2%-4678.6%
EBT Margin-668.8%-4893.4%
Tax Rate1.7%0.0%

Financial Health

MetricGLUEPRME
Current Ratio10.58x3.05x
D/E Ratio0.42x5.26x
Financial Leverage1.42x6.26x
Working Capital$572M$65M

Cash Flow

MetricGLUEPRME
Operating Cash Flow-$24M-$156M
Free Cash Flow-$32M-$157M
Capital Spending-$8M-$800K
OCF Growth YoY-186.8%–
FCF Growth YoY-234.5%–
FCF/Sales-130.8%–
CapEx/Sales32.7%–

Operational Efficiency

MetricGLUEPRME
Asset Turnover0.04x–
Fixed Assets Turnover0.8x–

Income Statement

MetricGLUEPRME
Total Revenue$25M–
Operating Income-$182M-$197M
Net Income-$161M-$188M
R&D Expense$171M$146M

Dividend & Shareholder Information

MetricGLUEPRME
Shares Outstanding85M181M
Net Income Growth-766.6%–
EPS Growth-540.0%–
FAQ

GLUE vs PRME: stock comparison and AI forecast

Which is bigger, GLUE or PRME?

GLUE is 1.1 times larger than PRME by market capitalization ($907M against $805M).

Which one does Intratio's AI model rank higher, GLUE or PRME?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.